|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 10, 2017 ) Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Intermittent Claudication - Pipeline Review, H1 2017, provides an overview of the Intermittent Claudication (Cardiovascular) pipeline landscape.
Intermittent claudication is caused by narrowing or blockage in the main artery that takes blood to leg. Symptoms include burning or tingling sensation, decreased or absent pulse in the lower limb, pale or bluish skin, poor hair growth on the legs and sores or wounds on the lower limb that heal slowly, poorly. Risk factors include smoking, high cholesterol, high blood pressure, obesity, diabetes, age and family history.
Report Highlights
Publisher's Pharmaceutical and Healthcare latest pipeline guide Intermittent Claudication - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Intermittent Claudication (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Request a Sample at http://www.reportsweb.com/inquiry&RW0001689423/sample
The Intermittent Claudication (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Intermittent Claudication and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Discovery stages are 1, 4 and 1 respectively.
Intermittent Claudication (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Browse Complete Report http://www.reportsweb.com/intermittent-claudication-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Intermittent Claudication (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Intermittent Claudication (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Intermittent Claudication (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Intermittent Claudication (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Intermittent Claudication (Cardiovascular)
Get discount on report purchase at http://www.reportsweb.com/inquiry&RW0001689423/discount
Key Point from Table of Contents:
Publisher Report Coverage
Intermittent Claudication - Overview
Intermittent Claudication - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Intermittent Claudication - Companies Involved in Therapeutics Development
Genovate Biotechnology Co LTD
ID Pharma Co Ltd
Kowa Company Ltd
Nuo Therapeutics Inc
Pluristem Therapeutics Inc
Intermittent Claudication - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001689423/buy/2600
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
